Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation.
New fundamentals in hemostasis.
Versteeg HH, Heemskerk JW, Levi M, Reitsma PH.
Physiol Rev. 2013 Jan;93(1):327-58. doi: 10.1152/physrev.00016.2011.
Advances in monitoring anticoagulant therapy.
Božič Mijovski M.
Adv Clin Chem. 2019;90:197-213. doi: 10.1016/bs.acc.2019.01.005. Epub 2019 Feb 21.
Pearls and pitfalls in factor inhibitor assays.
Adcock DM, Favaloro EJ.
Int J Lab Hematol. 2015 May;37 Suppl 1:52-60. doi: 10.1111/ijlh.12352.
Factor X.
Jackson CM.
Prog Hemost Thromb. 1984;7:55-109.
The safety of pharmacologic options for the treatment of persons with hemophilia.
Franchini M, Mannucci PM.
Expert Opin Drug Saf. 2016 Oct;15(10):1391-400. doi: 10.1080/14740338.2016.1208747. Epub 2016 Jul 18.
Autoantibodies to coagulation factors: from pathophysiology to diagnosis and therapy.
Cugno M, Gualtierotti R, Tedeschi A, Meroni PL.
Autoimmun Rev. 2014 Jan;13(1):40-8. doi: 10.1016/j.autrev.2013.08.001. Epub 2013 Aug 14.
Detection and Measurement of Factor Inhibitors.
Kershaw G.
Methods Mol Biol. 2017;1646:295-304. doi: 10.1007/978-1-4939-7196-1_23.
Nature of von Willebrand factor: a new assay and a specific inhibitor.
Sarji KE, Stratton RD, Wagner RH, Brinkhous KM.
Proc Natl Acad Sci U S A. 1974 Aug;71(8):2937-41. doi: 10.1073/pnas.71.8.2937.
One-stage vs. chromogenic assays in haemophilia A.
Potgieter JJ, Damgaard M, Hillarp A.
Eur J Haematol. 2015 Feb;94 Suppl 77:38-44. doi: 10.1111/ejh.12500.
[Acquired coagulant factor inhibitors].
Nogami K.
Rinsho Ketsueki. 2015 Feb;56(2):160-8. doi: 10.11406/rinketsu.56.160.
